NCIC CLINICAL TRIALS GROUP

GYNECOLOGY

OVARIAN WORKING GROUP AGENDA

THE CHELSEA HOTEL, TORONTO, ON
ROOM: JAMES
SATURDAY MAY 2, 2014 8:00 A.M – 9:00 A.M
CHAIRS: DIANE PROVENCHER AND HELEN MACKAY

CME Credits:
Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen’s University.

Learning Objectives:
To review new insights in the biology of ovarian cancer
To review the landscape of clinical trials in ovarian cancer
To review study contents/clinical trial proposals in ovarian cancer
To review existing partnerships and opportunities for new partnerships in ovarian cancer

1. Introduction - Canadian Ovarian trials landscape  Mackay
2. Open trials
   • OV.21 Provencher/Mackay
   • OV.23 Wilson/Oza
   • OV.24 Lheureux/Oza
3. Proposed Trials
   • GOG 281
     A Randomized Phase II/III Study To Assess the Efficacy of Trametinib (GSK 1120212) in Patients with Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer
     Open in the US and open in the UK
   • NRG-GY004 (GYN 9813)
     A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum Based Chemotherapy in Women with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
     Competes with NCIC CTG IND study
NRG OV1405 (GYN 9814)

A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent/persistent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS)

Competes with NCIC CTG IND study

4. IND Updates Tinker
5. PMH consortium update Oza
6. Any other business